The Food and Drug Administration (FDA) is reviewing an ER formulation of alfuzosin hydrochloride 10 mg for once-daily administration for treatment of symptomatic BPH. The IR and twice-daily ER ...
Alfuzosin is contraindicated in patients with a hypersensitivity to alfuzosin or other quinazolones. Alfuzosin should be used cautiously in patients who are predisposed to hypotension, including ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback